Moreover, recent preclinical studies have indicated that bivalent CD73/PD-1 antibodies significantly improve the activation of tumor-infiltrating lymphocytes (67, 68), implying that our triple-drug treatment might enhance treatment response if combined with FDA-approved anti-PD-1 therapies such as pembrolizumab. This evidence concerns the gene NT5E and neoplasm.